NasdaqCM - Delayed Quote • USD
Corcept Therapeutics Incorporated (CORT)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:33 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 4 |
Avg. Estimate | 0.22 | 0.25 | 1.02 | 1.28 |
Low Estimate | 0.19 | 0.2 | 0.84 | 0.97 |
High Estimate | 0.26 | 0.31 | 1.15 | 1.48 |
Year Ago EPS | 0.14 | 0.25 | 0.94 | 1.02 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 4 |
Avg. Estimate | 141.2M | 150.69M | 610.64M | 665.77M |
Low Estimate | 136M | 146.44M | 600.14M | 635M |
High Estimate | 145.84M | 154.44M | 621.95M | 707.97M |
Year Ago Sales | 105.65M | 109.69M | 482.38M | 610.64M |
Sales Growth (year/est) | 33.60% | 37.40% | 26.60% | 9.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.19 | 0.15 | 0.22 | 0.26 |
EPS Actual | 0.14 | 0.25 | 0.28 | 0.28 |
Difference | -0.05 | 0.1 | 0.06 | 0.02 |
Surprise % | -26.30% | 66.70% | 27.30% | 7.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.22 | 0.25 | 1.02 | 1.28 |
7 Days Ago | 0.22 | 0.25 | 1.02 | 1.28 |
30 Days Ago | 0.23 | 0.27 | 1.09 | 1.38 |
60 Days Ago | 0.23 | 0.27 | 1.09 | 1.38 |
90 Days Ago | 0.23 | 0.25 | 1.01 | 1.73 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | CORT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 57.10% | -- | -- | 6.50% |
Next Qtr. | 0.00% | -- | -- | 12.00% |
Current Year | 8.50% | -- | -- | 5.30% |
Next Year | 25.50% | -- | -- | 13.10% |
Next 5 Years (per annum) | -41.40% | -- | -- | 11.09% |
Past 5 Years (per annum) | 4.84% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/23/2024 |
Maintains | Truist Securities: Buy to Buy | 2/16/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 1/2/2024 |
Maintains | Canaccord Genuity: Buy to Buy | 12/13/2023 |
Upgrade | Truist Securities: Hold to Buy | 11/6/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 11/2/2023 |
Related Tickers
CYTK Cytokinetics, Incorporated
65.34
+0.83%
IMVT Immunovant, Inc.
27.17
-2.09%
JANX Janux Therapeutics, Inc.
47.39
+0.62%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
KURA Kura Oncology, Inc.
19.65
+3.42%
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
BPMC Blueprint Medicines Corporation
93.00
+2.50%
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
PTCT PTC Therapeutics, Inc.
28.57
+12.08%